Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Filters applied: . Clear all
Page 1
Treatment with somatostatin analogs and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas.
Maiza JC, Vezzosi D, Grunenwald S, Otal P, Guimbaud R, Bennet A, Caron P. Maiza JC, et al. J Endocrinol Invest. 2011 Oct;34(9):e253-8. doi: 10.3275/7762. Epub 2011 May 27. J Endocrinol Invest. 2011. PMID: 21623151
BACKGROUND: Preventing hypoglycemia is of vital importance and a major challenge in patients with severe symptomatic hypoglycemia related to malignant unresectable insulinomas, but there is no consensus treatment. ...CONCLUSION: Chemoe
BACKGROUND: Preventing hypoglycemia is of vital importance and a major challenge in patients with severe symptomatic hypogl
[Malignant insulinoma].
Tóth M, Szücs N, Jakab Z, Doros A, Nemes Z, Rácz K. Tóth M, et al. Orv Hetil. 2011 Mar 6;152(10):398-402. doi: 10.1556/OH.2011.29058. Orv Hetil. 2011. PMID: 21354956 Hungarian.
Octreotide scintigraphy disclosed abundant expression of somatostatin receptors both on primary tumor and hepatic metastases. 90Yttrium-DOTATOC treatment was performed in three sessions within 9 months (3 x 200 mCi) with a mixed therapeutic response. ...Serum …
Octreotide scintigraphy disclosed abundant expression of somatostatin receptors both on primary tumor and hepatic metastases. …
Feedback